Insights · Regulatory record
An FDA committee recommended six peptides for compounding. Here is what that does and does not mean.
Published 2026-08-29 · Sources cited below
On July 23–24, 2026, the U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee (PCAC) evaluated seven peptides and voted to recommend six of them — BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax — for inclusion on the 503A Bulks List. One peptide, emideltide (DSIP), was rejected. The National Community Pharmacists Association reported the outcome directly: "The Food and Drug Administration's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend that the FDA include peptides BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax on the 503A Bulks List."
If you follow peptide communities, you have probably seen this vote described as everything from "FDA approval" to "legalization." It is neither. This page records what the vote actually is, and what the research record says about each compound involved.
What the recommendation is
The 503A Bulks List names bulk drug substances that licensed compounding pharmacies may use to prepare medications under section 503A of the Food, Drug, and Cosmetic Act. A PCAC vote is an advisory recommendation to FDA. It is not binding: FDA must still act on the recommendation before any of these peptides are added to the list, and as of this article's publication date, FDA has not done so.
The vote is still a meaningful signal. For several of these compounds it reverses years of restrictive posture — BPC-157, for example, sat in FDA's Category 2 ("significant safety risks") bulk-substances table until an April 2026 restructuring removed it after its original nomination was withdrawn, a procedural change rather than a new safety finding.
What the recommendation is not
It is not FDA approval. None of the six peptides has been through a new drug application. No agency reviewed manufacturing consistency, efficacy for a claimed indication, or a label's worth of safety documentation, because for these compounds no such label exists.
It is not an efficacy determination. A 503A listing addresses what pharmacies may legally compound — it says nothing about whether a compound does what its marketing claims. The committee did not evaluate the questions most buyers actually have.
It is not a safety endorsement. The controlled human safety record for most of these compounds is thin to absent, and a compounding pathway does not change that.
What the research record says, compound by compound
Each entry links to the full BioStack dossier: sources, verbatim quotes, evidence grades, and the gaps, graded by our public methodology.
A 2025 systematic review located 36 studies and identified one human clinical study, reporting that no clinical safety data were found. The bulk of the literature is preclinical.
KPVdossier in final review
The controlled evidence base is animal-model work, notably in experimental colitis. No controlled human efficacy trials were located in our research pass.
Marketed widely for recovery; the human trial record for the gray-market fragment product is thin, and claims frequently extrapolate from preclinical thymosin beta-4 research.
A mitochondrial-derived peptide with mechanistic and early human data. Our dossier grades its efficacy claims as insufficient pending controlled human trials.
Epitalondossier in final review
Most human data trace to Russian studies of the related epithalamin preparation. Telomerase-related claims carry an unresolved benefit-versus-risk question that our dossier keeps under review.
Semaxdossier in final review
A Russian-registered drug with human stroke studies of limited size and design. It holds no FDA approval, and its label-grade safety documentation is not available from U.S. regulators.
What happens next
FDA decides whether to adopt the committee's recommendation. There is no statutory deadline. Until FDA acts, none of the six peptides is on the 503A Bulks List, and their regulatory status is unchanged. We re-verify the primary FDA sources in our dossiers when that status changes, and each dossier records the date its regulatory claims were last checked against the live record.
BioStack does not sell, recommend, or advise on any compound. This page, like every dossier, is an educational record of what is known — and what is not.
Sources
- National Community Pharmacists Association, "FDA advisory committee nominates six peptides for pharmacies to compound," qAM, July 31, 2026.
- U.S. FDA, "Certain bulk drug substances for use in compounding that may present significant safety risks" (live listing; April 2026 restructuring), accessed August 2026.
- Primary literature and regulatory sources for each compound are cited with verbatim quotes inside the linked dossiers.